Accéder au contenu
Merck

Design and synthesis of Rho kinase inhibitors (I).

Bioorganic & medicinal chemistry (2004-04-15)
Atsuya Takami, Masayuki Iwakubo, Yuji Okada, Takehisa Kawata, Hideharu Odai, Nobuaki Takahashi, Kazutoshi Shindo, Kaname Kimura, Yoshimichi Tagami, Mika Miyake, Kayoko Fukushima, Masaki Inagaki, Mutsuki Amano, Kozo Kaibuchi, Hiroshi Iijima
RÉSUMÉ

Several structurally unrelated scaffolds of the Rho kinase inhibitor were designed using pharmacophore information obtained from the results of a high-throughput screening and structural information from a homology model of Rho kinase. A docking simulation using the ligand-binding pocket of the Rho kinase model helped to comprehensively understand and to predict the structure-activity relationship of the inhibitors. This understanding was useful for developing new Rho kinase inhibitors of higher potency and selectivity. We identified several potent platforms for developing the Rho kinase inhibitors, namely, pyridine, 1H-indazole, isoquinoline, and phthalimide.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
1-Boc-4-piperidone, 98%